Picard Medical / SynCardia Highlight Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health

Picard Medical (NYSE American: PMI) highlighted a UCSF Health case in which a patient in his twenties was supported on the SynCardia Total Artificial Heart for 119 days before a successful heart transplant on March 14, 2026.

Rhea-AI Summary

Picard Medical (NYSE American: PMI) highlighted a UCSF Health case in which a patient in his twenties was supported on the SynCardia Total Artificial Heart for 119 days before a successful heart transplant on March 14, 2026.

This is the second of five UCSF patients bridged to transplant with the device, which is approved by the U.S. FDA and Health Canada, underscoring growing clinical adoption for advanced biventricular heart failure.

Positive

• 119-day SynCardia support before successful transplant
• Second of five UCSF patients bridged to transplant
• Implant on Nov 15, 2025 and transplant on Mar 14, 2026
• Device approved by U.S. FDA and Health Canada
• Demonstrates adoption at a leading transplant center

Negative

• None.

Argus Mar 19 session

-3.45% close to close Open Argus

Details

News Market Reaction – PMI

On Mar 19, the day this news came out, PMI closed 3.45% below the previous close.

Data tracked by StockTitan Argus for the Mar 19 session.

Market Context

This announcement highlights a successful 119-day SynCardia Total Artificial Heart bridge to transpl...

Analysis

This announcement highlights a successful 119-day SynCardia Total Artificial Heart bridge to transplant, the second of five such UCSF cases, reinforcing the technology’s role in advanced biventricular heart failure. Recent history shows multiple positive clinical and visibility milestones, including conference presentations and media features. Alongside these, investors may track outcomes from the upcoming business update, previously disclosed financing-related proxy items, and how often such clinical successes translate into broader adoption trends over time.

Key Figures

Support duration: 119 days Implant date: November 15, 2025 Transplant date: March 14, 2026 +1 more

Support duration

119 days

SynCardia Total Artificial Heart bridge to transplant at UCSF Health

Implant date

November 15, 2025

SynCardia Total Artificial Heart implantation for young patient

Transplant date

March 14, 2026

Successful heart transplant following artificial heart support

Bridged patients at UCSF

2 of 5 patients

Second of five UCSF patients successfully bridged to transplant

Historical Context

5 past events · Latest: 2026-03-17

5 events

1. 2026-03-17

   Clinical case highlight

   24h Move

   -10.2%

   Four-year SynCardia Total Artificial Heart bridge-to-transplant case reported.

2. 2026-03-13

   Media feature

   24h Move

   -4.7%

   FOX Business BTV segment on SynCardia Total Artificial Heart and next-gen platform.

3. 2026-03-12

   Business update preview

   24h Move

   -4.7%

   Announcement of Annual Business Update webcast covering 2025 results and strategy.

4. 2026-03-02

   Conference data

   24h Move

   +0.0%

   Presentations of new clinical and preclinical data at THT 2026 conference.

5. 2026-02-26

   Training event

   24h Move

   -0.9%

   Participation in hands-on training day for SynCardia Total Artificial Heart at THT 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

total artificial heart, biventricular heart failure, bridge to transplant, redo sternotomy, +1 more

5 terms

total artificial heart medical

"maker of the world's first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

biventricular heart failure medical

"a patient in his twenties with advanced biventricular heart failure was successfully"

Biventricular heart failure is a condition where both the right and left sides of the heart are weakened and cannot pump blood effectively, like a two-pump system losing power on both ends. It matters to investors because it increases demand for treatments, medical devices, hospital care and long-term therapies, can drive clinical-trial activity and regulatory decisions, and may affect costs and revenue for companies in cardiovascular drugs, devices and healthcare services.

bridge to transplant medical

"successfully bridged to heart transplantation using the SynCardia Total Artificial Heart"

A bridge to transplant is a temporary medical treatment or device used to keep a patient stable and alive while they wait for an organ transplant, such as a heart, lung, or liver. For investors, it signals a defined market for products and services that sustain patients during the waiting period—similar to a rental car keeping someone moving until their new car arrives—affecting demand, pricing, reimbursement and regulatory risk for related companies.

redo sternotomy medical

"second successful redo sternotomy, total artificial heart explant and heart transplant"

A redo sternotomy is a repeat surgical procedure in which a surgeon reopens the breastbone (sternum) to access the heart or nearby structures after a previous open‑chest operation. For investors, it signals higher medical risk, longer hospital stays, greater procedure costs and more complex device or implant management—like having to repair a previously opened car engine rather than working on a new one—which can affect hospitals’ costs, device makers’ outcomes and insurers’ payouts.

mechanical circulatory support medical

"Surgical Director of Heart Transplantation and Mechanical Circulatory Support at the"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Case highlights young patient supported for 119 days with the SynCardia Total Artificial Heart before successful heart transplantation

TUCSON, Ariz., March 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart failure was successfully bridged to heart transplantation using the SynCardia Total Artificial Heart. The patient, a male in his twenties, received the SynCardia Total Artificial Heart on November 15, 2025 to restore full circulatory support while awaiting a donor heart. After 119 days of support with the device, the patient underwent a successful heart transplant on March 14, 2026.

This case represents the second of five patients at UCSF Health who have been successfully bridged to transplantation using the SynCardia Total Artificial Heart, highlighting the role of total artificial heart therapy in supporting patients with advanced biventricular heart failure while they await a donor organ.

“We are pleased to have performed our second successful redo sternotomy, total artificial heart explant and heart transplant at UCSF and are happy to report that the patient is recovering well,” said Amy G. Fiedler, MD, Associate Professor of Cardiac Surgery and Surgical Director of Heart Transplantation and Mechanical Circulatory Support at the University of California San Francisco. “Our program values its partnership with SynCardia and the ability to bridge some of the sickest patients to successful heart transplantation.”

Cases such as this demonstrate the growing experience with total artificial heart therapy at leading transplant centers such as UCSF Health.

“We congratulate the physicians and care teams involved and are proud the SynCardia Total Artificial Heart provided critical time while this patient awaited transplantation. Adoption at leading transplant centers reflects the growing need for advanced mechanical circulatory support for patients with end-stage heart failure,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How long was the SynCardia Total Artificial Heart used before the March 14, 2026 transplant (PMI)?

The device supported the patient for 119 days before transplant. According to the company, the implant occurred on Nov 15, 2025 and the transplant took place on Mar 14, 2026, providing full circulatory support while awaiting a donor heart.

What does Picard Medical say about UCSF's experience with the SynCardia Total Artificial Heart (PMI)?

Picard Medical notes UCSF completed its second successful bridge-to-transplant case. According to the company, this case is the second of five UCSF patients successfully bridged using the SynCardia Total Artificial Heart.

Who was the patient supported by the SynCardia Total Artificial Heart at UCSF (PMI)?

The patient was a male in his twenties with advanced biventricular heart failure. According to the company, medical teams used the device to restore full circulatory support while awaiting a donor heart.

Does the SynCardia Total Artificial Heart have regulatory approvals relevant to U.S. patients (PMI)?

Yes, the SynCardia Total Artificial Heart is approved by the U.S. FDA and Health Canada. According to the company, these approvals support clinical use as a bridge to transplantation for eligible patients.

What clinical impact did Picard Medical highlight from the UCSF case (PMI)?

Picard Medical highlighted successful bridging to transplant and growing clinical experience. According to the company, the case shows the device provided critical time for a sick patient awaiting a donor heart at a leading transplant center.